MCP-1 as a potential target to inhibit the bone invasion by oral squamous cell carcinoma

Jingjing Quan1, Nigel A Morrison, Newell W Johnson

  • 1Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University & Guangdong Provincial Key Laboratory of Stomatology, Guangzhou, Guangdong 510055, China; School of Medical Science, Griffith University, QLD 4222, Australia.

Insights

Suppressing monocyte chemotactic protein-1 (MCP-1) expression inhibits oral squamous cell carcinoma (OSCC) bone invasion. This study shows MCP-1 inhibition reduces osteoclast formation, offering a potential therapeutic target for OSCC bone metastasis.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Bone invasion is a frequent complication of oral squamous cell carcinoma (OSCC).
  • Monocyte chemotactic protein-1 (MCP-1) plays a role in inflammatory processes and cancer metastasis.
  • Understanding MCP-1's role in OSCC bone invasion could reveal therapeutic targets.

Purpose of the Study:

  • To investigate the role of MCP-1 in OSCC bone invasion.
  • To explore the potential of suppressing MCP-1 to inhibit OSCC bone metastasis.

Main Methods:

  • Immunohistochemistry (IHC) and real-time PCR were used to assess MCP-1 expression in OSCC tissues and cell lines.
  • A dominant-negative MCP-1 variant (7ND) was used to transfect OSCC cells (SCC25).
  • In vitro osteoclast differentiation and in vivo mouse calvariae models were employed to evaluate the effect of MCP-1 suppression on bone invasion.

Main Results:

  • MCP-1 was highly expressed in OSCC tissues and cell lines, with SCC25 showing the highest expression.
  • Transfected SCC25 cells (SCC25-7ND) with suppressed MCP-1 expression significantly inhibited osteoclast formation in vitro.
  • In vivo studies demonstrated that SCC25-7ND cells caused significantly less osteoclast-mediated bone invasion compared to control SCC25 cells.

Conclusions:

  • MCP-1 expression is closely linked to bone invasion in OSCC.
  • Suppression of MCP-1 effectively inhibits osteoclast formation and subsequent bone invasion by OSCC.
  • MCP-1 represents a promising therapeutic target for preventing or treating OSCC bone metastasis.

Related Concept Videos